Coherus Oncology (CHRS) 2026 Global Healthcare Conference summary

Strategic vision and positioning

• Focused on overcoming immune resistance in oncology, leveraging Treg depletion and novel mechanisms.

• Commercial-stage with a launched product and a robust pipeline targeting multiple cancer indications.

• Positioned as the only approved therapy for nasopharyngeal cancer in its market.

• Emphasizes best-in-class selectivity and broad development for lead assets.

• Anticipates key data readouts for multiple programs in the current half-year.

Product and pipeline updates

• LOQTORZI, a next-gen PD-1 inhibitor, shows significant efficacy and survival benefit in nasopharyngeal cancer.

• Tagmokitug, a CCR8-targeting antibody, is in phase I/II trials across six indications, including head and neck, GI, and prostate cancers.

• Casdozokitug, a first-in-class IL-27 antagonist, is in a randomized three-arm study for first-line liver cancer.

• LOQTORZI is projected to reach $175 million annualized sales by 2026, with quarterly sales milestones supporting company operations.

• Pipeline strategy leverages LOQTORZI as both a revenue generator and combination partner for new assets.

Clinical development highlights

• Tagmokitug demonstrates high selectivity, ideal pharmacology, and proof of mechanism in tumor remodeling.

• Early data show manageable safety, with main adverse events being reversible enzyme elevations.

• Head and neck cohort shows promising activity, especially in HPV-positive and high TIRI score patients, with full data expected in October.

• GI and CRC cohorts are fully accrued, with ongoing data maturation; prostate cancer protocol to start soon.

• Casdozokitug combined with standard of care shows higher response and complete response rates than historical controls.